METHODS: This study was presented in accordance with the PRISMA protocol. This protocol is registered with the code CRD42019145410 in PROSPERO. We conducted a comprehensive literature search in databases, including Web of Science, PubMed/Medline, CINAHL Scopus, Cochrane Library, EMBASE, Science Direct, and EBSCO to find citations from the beginning of January 2019 until the beginning of April 2020 without any restrictions.
RESULTS: Finally, 51 studies, including 5,490 COVID-19 patients, were included in the present metaanalysis. The prevalence of different factors observed in laboratory findings was as follows: the prevalence of lymphopenia in patients with COVID-19 accounted for 51.6% (95% CI: 44.0-59.1), elevated C-reactive protein (CRP) was 63.6% (95% CI: 57.0-69.8), elevated erythrocyte sedimentation rate (ESR) was 62.5% (95% CI: 50.1-73.5), elevated tumor necrosis factor alpha (TNFα) was 28.7% (95% CI: 9.0-62.1), elevated serum amyloid-A level was 74.7% (95% CI: 50.0-89.7), elevated procalcitonin level was 72.6% (95% CI: 58.1-83.5), elevated interleukin-6 level was 59.9% (95% CI: 48.2-70.5), reduced CD3 level was 68.3% (95% CI: 50.1-82.2), reduced CD4 level was 62.0% (95% CI: 51.1- 71.6), elevated lactate dehydrogenase (LDH) level accounted for 53.1% (95% CI: 43.6-62.4), elevated brain natriuretic peptide (BNP) accounted for 48.9% (95% CI: 30.4-67.7), reduced albumin and reduced pre-albumin levels in patients with COVID-19 were estimated to be 54.7% (95% CI: 38.1-70.2) and 49.0% (95% CI: 26.6-71.8), and D-dimer level was 44.9% (95% CI: 31.0-59.6).
CONCLUSIONS: The results show lymphopenia, elevated ESR level, elevated CRP level, elevated serum amyloid-A, elevated TNFα, elevated procalcitonin level, elevated interleukin-6 level, reduced CD3, reduced CD4, elevated BNP, elevated LDH, reduced albumin, reduced pre-albumin, and elevated Ddimer levels as the most common findings at the time of admission.
方法:本研究按照PRISMA方案进行。此协议在PROSPERO中注册了代码CRD42019145410。我们在数据库中进行了全面的文献检索,包括WebofScience,PubMed/Medline,CINAHLScopus,科克伦图书馆,EMBASE,科学直接,和EBSCO寻找从2019年1月初到2020年4月初的引文,没有任何限制。
结果:最后,51项研究,包括5490例COVID-19患者,包括在本荟萃分析中。实验室发现的不同因素的患病率如下:COVID-19患者淋巴细胞减少的患病率为51.6%(95%CI:44.0-59.1),C反应蛋白(CRP)升高为63.6%(95%CI:57.0-69.8),红细胞沉降率(ESR)升高为62.5%(95%CI:50.1-73.5),肿瘤坏死因子α(TNFα)升高为28.7%(95%CI:9.0-62.1),血清淀粉样蛋白A水平升高为74.7%(95%CI:50.0-89.7),降钙素原水平升高为72.6%(95%CI:58.1-83.5),白细胞介素6水平升高为59.9%(95%CI:48.2-70.5),降低的CD3水平为68.3%(95%CI:50.1-82.2),CD4水平降低为62.0%(95%CI:51.1-71.6),乳酸脱氢酶(LDH)水平升高占53.1%(95%CI:43.6-62.4),脑钠肽(BNP)升高占48.9%(95%CI:30.4-67.7),COVID-19患者的白蛋白和前白蛋白水平降低估计为54.7%(95%CI:38.1-70.2)和49.0%(95%CI:26.6-71.8),D-二聚体水平为44.9%(95%CI:31.0-59.6)。
结论:结果显示淋巴细胞减少,ESR水平升高,CRP水平升高,血清淀粉样蛋白A升高,TNFα升高,降钙素原水平升高,白细胞介素-6水平升高,CD3降低,CD4降低,BNP升高,LDH升高,减少白蛋白,前白蛋白减少,和D二聚体水平升高是入院时最常见的发现。